Changing the way medicine is administered
TO LEARN MORE OR
FOR INVESTMENT OPPORTUNITIES...
WORLD WIDE OPPORTUNITIES
The PKA Micro-Needle addresses the increasing need to self-administer drugs in a painless, safe, and
• There are many injectable drug applications to sustain PKA SoftTouch for long term growth
• The device is truly a platform technology that can be easily adapted to other drug applications
• The PKA Micro-Needle is easliy adapted to both human and veterinary markets
• The Micro-Needle has high potential use for international vaccination markets to control the spread of Malaria, Ebola, Diphtheria, Cholera, Typhoid and other life-threatening diseases
Vaccines have a growing market worldwide; many of the features of the PKA Micro-Needle make it ideal for this market. Since the Micro-Needle specifically targets the skin, it is proven to be pain free and safe for all ages. The PKA Micro-Needle is disposable and user friendly.
Simple, Safe and Pain Free
Get the Facts...
An estimated 1.5 million children die each year from vaccine preventable diseases such as diarrhea and pneumonia.
More than 100 million children are immunized each year against tuberculosis, polio, measles, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type B, and, in some countries,
Vaccines save an estimated 2.5 million lives each year.
Compact and safe to use, the PKA
Micro-Needle can be applied almost anywhere on the body. This device is small in size and can be easily carried around in one's pocket. This makes it easy for soldiers to self inject to defend themselves against anthrax, typhoid fever, meningococcal disease and many other diseases.
Animal health just got easier. With the PKA Micro-Needle you will be able to self-administer your pet safely. It is estimated that $60 billion will be spent on pets in the U.S. for the year 2015, with $14.39 billion directly spent on animal medications.
3rd WORLD COUNTRIES
The PKA Micro-Needle will save time in administering vaccination injections to 3rd world countries. Since the Micro-Needle comes pre-measured and is a one-time application, this device makes it simple and easy to administer to large groups of people. The PKA Micro-Needle locks the needle inside after use, making this device easy and safe for disposal in the common household wastebasket.
HEPARIN: ANOTHER OPPORTUNITY
The Heparin market represents another opportunity for the application of our technology. Heparin is estimated to be a $3.0 billion market.
Heparin and low molecular weight versions are used to treat a wide range of clotting (thrombosis) disorders, both acute and chronic. Heparin is currently indicated for the treatment and prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolisms (PE) as well as for the prevention and treatment of Peripheral Arterial Embolism in Acute Coronary Syndromes (ACS).
DVT affects approximately 2 million people in the United States each year. In addition, more than 20 million people in the United States annually undergo major surgeries or have restricted mobility due to medical illnesses, which place them at risk for DVT.
Diabetes affects approximately 177 million people worldwide and is increasing, with the World Health Organization predicting 370 million diabetics by 2030.
The US alone has 20.8 million people suffering with diabetes. This equates to approximately 6% of the population.
It is the 6th most common cause of death as recorded on US death certificates.
The world-wide diabetes drug treatment market was valued at $19.2 billion in 2007.
The total sales for insulin products increased by 16.5% to total global sales of $5.0 billion.
DIABETES: HIGH-GROWTH MARKET
The Human Injectable Drug Market Potential (other than insulin)
$ 11,600 million
HEPARIN (Blood Clots, DVT, Strokes)
$ 3,500 million
PAIN MEDICATION (Cancer, Post Operative Surgery)
$ 2,200 million
PAIN MEDICATION (Migraines)
$ 1,800 million
$ 2,700 million
$ 200 million
$ 700 million
$ 300 million
$ 700 million
SEVERE ALLERGIC ASTHMA
$ 150 million
$ 150 million
$ 200 million
ALPHA 1 ANTITRIPSIN DEFICIENCY
$ 257 million
SICKLE CELL ANEMIA
$ 23.1 million
$ 18.7 million
$ 12.2 million
*Compounded Annual Growth Rate 6 Sources: National Gaucher Foundation; National Heart, Lung and Blood Institute; Calkins 1986; National Multiple Sclerosis Society; National Institute of Arthritis and Musculoskeletal and Skin Diseases; CDC2004; Alpha One Foundation; Genzyme Corp.; Rados2003; Business Communications Company, Inc; Vector Research-Global Technologies.
SAFE, SIMPLE & PAIN FREE
THE PKA MICRO-NEEDLE REPLACES THE SYRINGE WITH A PAINLESS INTERDERMAL DELIVERY SYSTEM